| Document |
Document Title |
|
JP2023014043A |
To provide a carboxylate and a carboxylic acid generator that can produce a resist pattern having excellent line edge roughness, and a resist composition comprising the same.The present invention provides a carboxylate represented by the...
|
|
JP2023014045A |
To provide a carboxylate and a carboxylic acid generator that can produce a resist pattern having excellent pattern collapse resistance, and a resist composition comprising the same.Specifically, a carboxylate represented by, for example...
|
|
JP2023014044A |
To provide a salt that can produce a resist pattern having excellent mask error factors, and a resist composition comprising the same.The present invention provides a salt represented by a specific structural formula, an acid generator a...
|
|
JP2022553107A |
Glucosylceramide synthase inhibitors and compositions containing same are disclosed. Also disclosed are methods of using glucosylceramide synthase inhibitors in the treatment of diseases and conditions where inhibition of glucosylceramid...
|
|
JP2022551470A |
Disclosed herein is formula (1): (1) novel compounds and salts thereof (wherein A, X, R1, R2, R3, R4, R10and R11are defined herein), and EP4It relates to its use in the treatment, prevention, amelioration, control or risk reduction of re...
|
|
JP2022551270A |
The present disclosure provides therapeutic compositions (i.e., therapeutic agents) and risk factors, symptoms and symptoms associated with Friedreich's ataxia (e.g., Complex I deficiency) to prevent or treat Friedreich's ataxia in mamma...
|
|
JP7185631B2 |
Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating d...
|
|
JP7182553B2 |
or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and composition...
|
|
JP7181118B2 |
To provide a carboxylate capable of producing a resist pattern with a good mask error factor, and a resist composition containing the carboxylate.A carboxylate represented by a formula (I) and a resist composition containing the carboxyl...
|
|
JP2022548594A |
The present invention provides compounds, compositions thereof, and methods of use thereof for the inhibition of USP30 and the treatment of USP30-mediated disorders.
|
|
JP2022173130A |
To provide a compound and a resist composition which allow a resist pattern having a good mask error factor (MEF) to be produced.There are provided: a compound represented by a formula (I); and a resist composition containing the compoun...
|
|
JP2022548312A |
The present application relates to lipids of formula (A-1) and compositions therewith. Lipid nanoparticles (eg, empty LNPs or loaded LNPs) include such lipids as well as additional lipids such as phospholipids, structured lipids, PEG lip...
|
|
JP2022173128A |
To provide a resist composition having a good focus margin (DOF).There are provided: a compound represented by a formula (I); and a resist composition containing the compound. [R1 represents *-R10 or *-L2-CO-O-R10; R2 represents *-CO-O-R...
|
|
JP7173350B2 |
The present invention provides a compound represented by formula [I] having an LPA1 receptor-antagonizing action, or a pharmaceutically acceptable salt thereof.
|
|
JP7170351B2 |
Provided are processes for monitoring and maintaining continuous carbonylation of epoxides or lactones. Processes include measuring parameters affecting the rate of the carbonylation reaction and adding supplemental replacement catalyst ...
|
|
JP7167168B2 |
Ketamine derivatives and pharmaceutical compositions thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used...
|
|
JP7158500B2 |
Provided is a compound of Formula (I):wherein the variable groups are defined herein.
|
|
JP2022543388A |
Provided herein are heterogeneous catalysts suitable for use in carbonylation reactions involving the production of acrylic acid from ethylene oxide and carbon monoxide on an industrial scale. Production includes, for example, a beta-pro...
|
|
JP2022541447A |
Kind Code: A1 Disclosed herein are benzenesulfonamide derivatives having formula (III), pharmaceutical compositions comprising the compounds, and proteins/polypeptides using the compounds to interfere with protein/polypeptide function, a...
|
|
JP2022540586A |
The present application relates to cannabinoid derivatives of formula (I) [Chemical 1] and pharmaceutical compositions containing them. Cannabinoid derivatives can be used to treat diseases associated with cannabinoid receptors such as p...
|
|
JP7138065B2 |
To provide a salt and a resist composition capable of producing a resist pattern with an excellent focus margin (DOF).There are provided a salt represented by formula (I), an acid generator, and a resist composition containing the same. ...
|
|
JP2022540434A |
The present disclosure provides cannabinoid derivatives having the structure of formula (I), [Chemical 1] Pharmaceutical compositions containing them, and methods of doing so using cannabinoid derivatives in subjects in need of treating ...
|
|
JP7125801B2 |
A compound, or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, according to formula (III) or according to Table A, a pharmaceutical composition comprising said compound and at least one pharmaceutically acceptable add...
|
|
JP2022533894A |
The present invention relates to arthropod control compositions comprising a compound of formula (I), methods and uses for controlling arthropods, and arthropod control articles comprising them.
|
|
JP2022530985A |
The present invention relates to the compounds of formula (IW-1) and their use in the treatment or prevention of inflammatory diseases or diseases associated with unwanted immune responses.A, RB, RC, And RDAs defined herein.
|
|
JP2022529642A |
A pharmaceutical composition comprising a compound useful for treating cancer and the above-mentioned compound is provided herein. Certain cancers include those mediated by YAP / TAZ or regulated by the interaction between YAP / TAZ and ...
|
|
JP7078089B2 |
To provide a polymerizable compound giving such properties when added to a solution comprising a polymerizable composition that the resultant polymerizable composition has high storage stability and can induce a liquid crystal phase alig...
|
|
JP2022525475A |
Suitable membrane separation systems and methods are provided herein for use in separating carbonylation catalysts from beta lactone product streams. Such membrane separation systems utilize cross-flow separation techniques and employ sw...
|
|
JP7064408B2 |
To provide: a composition capable of forming a thermoconductive sheet excellent in thermal conductivity in the film thickness direction; a thermoconductive sheet excellent in thermal conductivity in the film thickness direction; and a de...
|
|
JP7058119B2 |
To provide: a novel oxetane compound that has a high refractive index and a heat resistance, and a process for producing the same; and a curable composition containing the compound and a cured product thereof.The novel oxetane compound o...
|
|
JP7053264B2 |
Provided are processes for monitoring and maintaining continuous carbonylation of epoxides or lactones. Processes include measuring parameters affecting the rate of the carbonylation reaction and adding supplemental replacement catalyst ...
|
|
JP7034175B2 |
Disclosed are a fluorene oxime ester photoinitiator containing a polymerizable group, a preparation method and the use thereof, the fluorene oxime ester photoinitiator has the structure as shown in general formula (I), wherein R2 represe...
|
|
JP2022517434A |
INDUSTRIAL APPLICABILITY The present invention relates to a triglyceride prodrug based on lymph-mediated transport, and specifically relates to a triglyceride prodrug having different connecting chains for lymph-mediated transport, its p...
|
|
JP2022516575A |
Ketamine derivatives and pharmaceutical compositions thereof are disclosed. Ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation when administered orally. Ketamine derivatives can be used to trea...
|
|
JP7012852B2 |
The present invention relates to an ink composition for an organic light emitting device that can be applied to an inkjet process. When the inkjet process is applied using this, it is possible to form a film having smooth and flat surfac...
|
|
JP2022023958A |
To provide: a novel compound which has RAF/MEK complex stabilization activity and/or MEK inhibition activity and is useful for treating or preventing cell proliferative diseases; or a novel RAF/MEK complex stabilization agent or MEK inhi...
|
|
JP6999039B2 |
The present invention provides a photoinitiator containing fluorine fluorene oxime esters, a photocurable composition comprising the photoinitiator, and application of the photoinitiator. The photoinitiator has a structure represented by...
|
|
JP7013245B2 |
The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertensi...
|
|
JP2022510424A |
Compounds and complexes thereof that are capable of inhibiting the production of pathogenic bacterial metabolites are provided. Pharmaceutical compositions comprising them and methods of their use are also provided. [Selection diagram] None
|
|
JP6998081B2 |
The present invention provides nanofiltration membranes with reduced chemical reactivity that can be utilized in manufacturing processes where reactive feedstocks and/or products are utilized or produced. Methods of making and using the ...
|
|
JP2022507879A |
In the present invention, the formula (Ia) (in the formula, the XY group is -NHSO2-Or-SO2NH-is; R1Is H or alkyl; R2Is selected from COOH and tetrazolyl groups; R3Is selected from H, Cl and alkyl; R4Is selected from H, Cl and F; R5H, alky...
|
|
JP2022507020A |
A pharmaceutical composition comprising a compound useful for treating cancer and the above-mentioned compound is provided herein. Certain cancers include those mediated by YAP / TAZ or regulated by the interaction between YAP / TAZ and ...
|
|
JP2022003057A |
To provide treprostinil derivatives that can act as prodrugs of treprostinil.The present invention discloses a compound of formula (I), or a pharmaceutically acceptable salt thereof or the like (where R1 and R2 are independently hydrogen...
|
|
JP2022003066A |
To provide organic compounds useful for therapy and/or prophylaxis in a mammal, and in particular, compounds that are preferential agonists of the Cannabinoid Receptor 2.The invention relates to a compound represented by formula (I) in t...
|
|
JP2022501390A |
Isomer of formula compounds shown in (I), or a compound represented in formula (I), and stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, A pharmaceutically acceptable salt or prodrug. [Select...
|
|
JP2021193076A |
To provide a salt capable of producing a resist pattern having a good mask error factor (MEF), an acid generator and a resist composition containing the acid generator.There are provided a salt represented by the formula (I), an acid gen...
|
|
JP2021193075A |
To provide a carboxylate capable of producing a resist pattern having good line edge roughness (LER), a carboxylic acid generator and a resist composition.There are provided a carboxylate represented by the formula (I), a carboxylic acid...
|
|
JP2021534212A |
The invention includes novel aromatic molecules that can be used to treat pathological conditions such as cancer, skin disorders, muscle disorders and immune system related disorders, such as disorders of the hematopoietic system, includ...
|
|
JP6972525B2 |
An object of the present invention is to provide a spontaneous orientation auxiliary agent for a liquid crystal composition, the agent can ensure the preservability when the agent is added to a liquidcrystal composition, and can vertical...
|
|
JP2021178815A |
To provide a salt and an acid generator which make it possible to produce a resist pattern with excellent pattern collapse margin (PCM) and a resist composition comprising the same.The present invention discloses a carboxylate represente...
|
